Department of Science and Technology Studies, Rensselaer Polytechnic Institute, Troy, New York, USA.
Ann N Y Acad Sci. 2012 Feb;1248:124-39. doi: 10.1111/j.1749-6632.2011.06352.x. Epub 2012 Jan 18.
This paper traces the early 21st century success of the agonist-antagonist buprenorphine and the combination drug buprenorphine with naloxone within the broader quest to develop addiction therapeutics that began in the 1920s as the search for a nonaddictive analgesic. Drawing on archival research, document analysis, and interviews with contemporary actors, this paper situates the social organization of laboratory-based and clinical research within the domestic and international confluence of several issues, including research ethics, drug regulation, public attitudes, tensions around definitions of drug addiction, and the evolving roles of the pharmaceutical industry. The fervor that drove the champions of buprenorphine must be understood in relation to (1) the material work of research and pharmaceutical manufacturing; (2) the symbolic role of buprenorphine as a solution to numerous problems with addiction treatment evident by the mid-1970s; the destigmatization and individualization of addicts as patients; and (3) the complex configurations of public and private partnerships.
本文追溯了 21 世纪早期激动剂拮抗剂丁丙诺啡和丁丙诺啡与纳洛酮联合药物的成功，这一成功源于 20 世纪 20 年代开始的寻找非成瘾性镇痛药的广泛探索，以开发治疗成瘾的方法。本文通过档案研究、文献分析和对当代参与者的访谈，将基于实验室和临床的研究的社会组织置于国内和国际几个问题的融合之中，包括研究伦理、药物监管、公众态度、对药物成瘾定义的紧张关系，以及制药行业角色的不断演变。推动丁丙诺啡发展的热情必须与以下因素相关联：（1）研究和制药的实际工作；（2）丁丙诺啡作为解决 20 世纪 70 年代中期明显的成瘾治疗问题的解决方案的象征作用；将成瘾者作为患者进行去污名化和个体化；以及（3）公共和私人合作伙伴关系的复杂配置。
